Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Pfizer Inc. is one of them.

Pfizer Inc. (NYSE:PFE), a global biopharmaceutical leader, continues to make strides in vaccines and oncology, reinforcing its position in the pharma sector.

In September 2025, PFE and BioNTech reported positive Phase 3 data for the LP.8.1-adapted COMIRNATY 2025-2026 COVID-19 vaccine. The updated formulation produced at least a four-fold increase in neutralizing antibodies among adults 65+ and high-risk adults 18–64, while maintaining a strong safety profile. The vaccine demonstrated robust protection against emerging SARS-CoV-2 sublineages and has been submitted to the FDA to support ongoing authorization for vulnerable populations during upcoming flu seasons. These advancements contribute to Pfizer’s standing among the best pharmaceutical stocks for both vaccines and broader healthcare solutions.

Beyond infectious disease, Pfizer Inc. (NYSE:PFE) is advancing its oncology pipeline, with notable successes in combination therapies. The PADCEV plus KEYTRUDA regimen improved survival in bladder cancer patients, while XTANDI with leuprolide significantly benefited high-risk metastatic prostate cancer patients. These developments highlight the corporation’s focus on expanding critical cancer treatments alongside its vaccine portfolio.

Strategically, Pfizer Inc. (NYSE:PFE) aims to achieve $4.5 billion in cost reductions by year-end 2025, reinvesting savings into R&D for innovative therapies as some key patents approach expiration. Licensing agreements, such as the recent deal with China’s 3SBio, expand access to experimental oncology therapies targeting multiple tumor types. Financial performance remains strong, supported by sales of its COVID-19 vaccine, Paxlovid, and growth in oncology and hematology segments.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.